Myocarditis Pipeline Insight

DelveInsight’s, “Myocarditis – Pipeline Insight, 2022,” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Myocarditis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Myocarditis Understanding

Myocarditis: Overview

Myocarditis is the inflammation of the heart muscle, which is also known as the myocardium. Myocarditis directly affects the heart muscle and thereby affecting the heart’s electrical system, which in turn causes abnormal or rapid heart rhythms (arrhythmias) and reduces heart’s ability to pump blood. The condition usually occurs due to a viral infection but may also be caused as a result of a reaction from consumption of a drug. Severe myocarditis may even lead to blood clots eventually leading to a heart stroke.


Symptoms

Symptoms of mild myocarditis are not severe; there may even be no symptoms at all. In advanced form, the symptoms of myocarditis can range from fatigue, chest pain, and fluid retention with swelling in feet, ankles, and legs to shortness of breath, arrhythmias and joint pain, headaches, fever, diarrhea and a sore throat.


Diagnosis

Diagnosis of myocarditis is done by referring to the test results of various tests, such as chest X-ray, electrocardiogram (ECG), MRI, blood tests, echocardiogram, and cardiac catheterization and endomyocardial biopsy.


Treatment

Myocarditis treatment depends on the source and intensity of the infection. Some commonly prescribed medication for the treatment of myocarditis are antibiotic therapy, corticosteroid therapy, diuretic therapy, cardiac medication such as ACE inhibitor, beta-blocker, or ARB, and some lifestyle changes may also be suggested, such as a low-salt diet and fluid restriction.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Myocarditis R&D. The therapies under development are focused on novel approaches to treat/improve Myocarditis.

Myocarditis Emerging Drugs Chapters

This segment of the Myocarditis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Myocarditis Emerging Drugs


CAN10: Cantargia AB

Cantargia AB’s CAN10 is currently in the preclinical phase of drug development. CAN10 is a new antibody which is being developed against IL1RAP. The company is aiming to develop this antibody for the treatment of inflammatory and autoimmune diseases which involve these interleukin pathways (IL-1, IL-33, and IL-36).


Cannabidiol: Cardiol Therapeutics

Cannabidiol, also known as CARDIOLRX, is being developed by Cardiol Therapeutics for the treatment of acute myocarditis. The mechanism of action of CBD is not completely understood. However, it is known that it acts on cannabinoid receptors which are a part of the endocannabinoid system, and these receptors are present in various areas of the body. Currently, the company is carrying out the Phase I study of the drug candidate and soon plans to conduct a Phase II study to evaluate the effects of the drug on myocardial recovery in acute myocarditis patients.

Further product details are provided in the report……..

Myocarditis: Therapeutic Assessment

This segment of the report provides insights about the different Myocarditis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Myocarditis

There are approx. 2+ key companies which are developing the therapies for Myocarditis. The companies which have their Myocarditis drug candidates in the discovery to early-stage, i.e. Phase I include, Cardiol Therapeutics and others.

Phases

DelveInsight’s report covers around 2+ products under different phases of clinical development like

  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Myocarditis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myocarditis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase I, preclinical and discovery stage. It also analyses Myocarditis therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myocarditis drugs.

Myocarditis Report Insights

  • Myocarditis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Myocarditis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Myocarditis drugs?
  • How many Myocarditis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myocarditis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Myocarditis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Myocarditis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Myocarditis: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Myocarditis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Myocarditis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Myocarditis Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Early Stage Products (Phase I)

  • Comparative Analysis

Cannabidiol: Cardiol Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical Products

  • Comparative Analysis

CAN10: Cantargia AB

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Discovery Stage Products

  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Myocarditis Key Companies

Myocarditis Key Products

Myocarditis- Unmet Needs

Myocarditis- Market Drivers and Barriers

Myocarditis- Future Perspectives and Conclusion

Myocarditis Analyst Views

Myocarditis Key Companies

Appendix

List of Table

Table 1: Total Products for Myocarditis

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Myocarditis

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Cantargia AB

• Cardiol Therapeutics

• Apitope

Forward to Friend

Need A Quote